CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cocrystal Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cocrystal Pharma Inc
19805 N Creek Pkwy
Phone: (786) 459-1831p:786 459-1831 BOTHELL, WA  98011-8251  United States Ticker: COCPCOCP

Business Summary
Cocrystal Pharma, Inc. is a biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. It is developing antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It also uses advanced computational methods to screen and design product candidates using proprietary cocrystal structural information. The Company’s pipeline CC-42344 is an oral PB2 inhibitor discovered using Cocrystals proprietary structure-based drug discovery platform technology. It is specifically designed to be effective against all pandemic and seasonal influenza A strains and to have a high barrier to resistance due to the way the virus replication machinery is targeted.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Roger D.Kornberg 76 5/1/2021 4/15/2020
President, Co-Interim Chief Executive Officer SamLee 63 5/27/2021 1/2/2014
Co-Interim Chief Executive Officer, Chief Financial Officer James J.Martin 56 5/27/2021 2/27/2017
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Cocrystal Discovery, Inc. 19805 N Creek Pkwy Bothell WA United States

Business Names
Business Name
BioZone Laboratories, Inc.
COCP
COCPD
5 additional Business Names available in full report.

General Information
Number of Employees: 12 (As of 3/21/2023)
Outstanding Shares: 10,173,790 (As of 11/13/2023)
Shareholders: 434
Stock Exchange: NASD
Federal Tax Id: 205978559
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024